Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924805 | 0.94 | TSHR (0.41) | CALCRLTSHRTDP1AKR1B1AKR1A1 | |
| SCHEMBL1727271 | 0.89 | TDP2 (0.42) | CALCRLAKR1B1AKR1A1TDP2CMA1 | |
| SCHEMBL13055196 | 0.83 | CALCRL (0.43) | CALCRLTSHRTDP1AKR1B1RAMP1 | |
| SCHEMBL1715181 | 0.82 | CALCRL (0.43) | CALCRLTSHRTDP1AKR1B1RAMP1 | |
| SCHEMBL14536414 | 0.82 | CALCRL (0.43) | CALCRLTSHRTDP1AKR1B1RAMP1 | |
| SCHEMBL26401054 | 0.81 | METAP1 (0.38) | TDP2ASIC3CMA1AHRBACE1 | |
| Hydrochloric Acid SCHEMBL1714778 | 0.81 | CALCRL (0.42) | CALCRLTSHRTDP1AKR1B1RAMP1 | |
| Tetrantoin SCHEMBL29582305 | 0.79 | TSHR (0.54) | CALCRLTSHRTDP1AKR1B1 | |
| Tetrantoin SCHEMBL79518 | 0.79 | TSHR (0.54) | CALCRLTSHRTDP1AKR1B1 | |
| SCHEMBL4960953 | 0.78 | CALCRL (0.50) | CALCRLTSHRTDP1RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-1912653-B1 | HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2011070283-A8 | METHOD AND APPARATUS FOR COOLING AND/OR DEEP-FREEZING MATERIALS IMPLEMENTING THE INJECTION OF TWO CRYOGENIC LIQUIDS | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-1606264-B1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
| US-20060189593-A1 | Aryl spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-24 | — | — | US | disclosed |
| US-20060189600-A1 | Benodiazepine spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-24 | — | — | US | disclosed |
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006031676-A2 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1606264-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004083187-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CALCRL 2338/4885TSHR 396/4885TDP1 1693/4885 |
| US-20060189600-A1 | Benodiazepine spirohydantoin cgrp receptor antagonists | BDKRB2, BDKRB1, CNR2 | CALCRL 7/4885TSHR 1061/4885TDP1 3028/4885 |
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | CALCRL, CALCR, CCKAR | CALCRL 1/4885TSHR 1059/4885TDP1 3851/4885 |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | BDKRB2, CALCRL, CCKBR | CALCRL 2/4885TSHR 986/4885TDP1 3490/4885 |
| US-20060189593-A1 | Aryl spirohydantoin cgrp receptor antagonists | CALCRL, BDKRB2, MRGPRX1 | CALCRL 1/4885TSHR 732/4885TDP1 2834/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | CALCRL 2683/4885TSHR 504/4885TDP1 1667/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CALCRL 2338/4885TSHR 396/4885TDP1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.